Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company (NYSE:LLY) is a research-driven pharmaceutical leader headquartered in In ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...

Investing.com -- Eli Lilly and Company (NYSE:LLY) is expanding its neuroscience pipeline through the acquisition of SiteOne Therapeutics in a deal worth up to $1 billion, deepening its bet on ...

Lilly and Danish rival Novo Nordisk are market leaders for a class of weight-loss treatments known as GLP-1 agonists, which work by suppressing appetite. While its widely popular drugs Zepbound and ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite contro ...